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Mortality Differences Between Traditional 
Medicare and Medicare Advantage:  
A Risk-Adjusted Assessment Using  
Claims Data
Roy A. Beveridge, MD1, Sean M. Mendes, BS1, Arial Caplan, BS1,  
Teresa L. Rogstad, MPH1, Vanessa Olson, BA1, Meredith C. Williams, MD1, 
Jacquelyn M. McRae, PharmD2, and Stefan Vargas, PharmD2
Abstract
Medicare Advantage (MA) has grown rapidly since the Affordable Care Act; nearly one-third of Medicare beneficiaries now 
choose MA. An assessment of the comparative value of the 2 options is confounded by an apparent selection bias favoring 
MA, as reflected in mortality differences. Previous assessments have been hampered by lack of access to claims diagnosis data 
for the MA population. An indirect comparison of mortality as an outcome variable was conducted by modeling mortality 
on a traditional fee-for-service (FFS) Medicare data set, applying the model to an MA data set, and then evaluating the ratio 
of actual-to-predicted mortality in the MA data set. The mortality model adjusted for clinical conditions and demographic 
factors. Model development considered the effect of potentially greater coding intensity in the MA population. Further 
analysis calculated ratios for subpopulations. Predicted, risk-adjusted mortality was lower in the MA population than in FFS 
Medicare. However, the ratio of actual-to-predicted mortality (0.80) suggested that the individuals in the MA data set were 
less likely to die than would be predicted had those individuals been enrolled in FFS Medicare. Differences between actual and 
predicted mortality were particularly pronounced in low income (dual eligibility), nonwhite race, high morbidity, and Health 
Maintenance Organization (HMO) subgroups. After controlling for baseline clinical risk as represented by claims diagnosis data, 
mortality differences favoring MA over FFS Medicare persisted, particularly in vulnerable subgroups and HMO plans. These 
findings suggest that differences in morbidity do not fully explain differences in mortality between the 2 programs.
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Original Research
Background
In 2015, 31% of current Medicare beneficiaries were 
enrolled in a private managed care plan (Medicare Advantage 
[MA]) rather than the default option of federally adminis-
tered traditional fee-for-service (FFS) Medicare.1 The origi-
nal proponents of MA saw the potential for improved quality 
of care, which could lead to better health outcomes when 
compared with those of FFS Medicare.2 However, the abil-
ity of MA to achieve these goals has not been fully demon-
strated. A recent systematic review published by the Kaiser 
Family Foundation described the evidence regarding the 
relative impact of MA on actual objective health outcomes 
and mortality as outdated and characterized by insufficient 
control for selection bias.3 Some studies comparing mortal-
ity and/or switching rates between MA and FFS Medicare 
have concluded that differences suggest selection bias 
favorable to MA, but authors have also acknowledged that 
the lack of publicly available claims diagnosis data for the 
MA population limits comparisons between the 2 popula-
tions. In other words, an adjustment for underlying morbid-
ity might improve comparisons of mortality between FFS 
Medicare and MA.4-7
Only 1 comparison of FFS Medicare and MA published 
since 2000 has addressed mortality differences with control 
for selection bias due to differences in morbidity.8 This study 
concluded that a favorable selection bias does not explain the 
lower rates of mortality observed in MA. The study relied on 
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self-reported morbidity data collected through the 1996 and 
1998 Medicare Current Beneficiary Survey.
The present study compared mortality between the MA 
population covered by Humana Inc, a large health and well-
ness company with more than 1.9 million MA enrollees as of 
December 31, 2012, the end of the study period, and an FFS 
Medicare sample with correction for selection bias through 
adjustment for chronic conditions and demographic factors, 
with consideration of the potential for bias due to greater 
coding intensity in MA plans. Further analysis calculated 
ratios for subgroups. The study builds on previous research 
by conducting an evaluation from a recent time frame and 
with adjustment for morbidity.
Methods
Modeling Design
An indirect comparison of mortality between MA and FFS 
Medicare was conducted by modeling person-level mortality 
on an FFS Medicare data set, applying the model to an MA 
data set, and then evaluating the ratio of actual-to-predicted 
mortality rates in the MA data set. The predicted MA mortal-
ity rate would represent the probability of mortality if the 
individuals were enrolled in FFS Medicare, that is, the rate 
that one would expect to observe if enrollment in MA had no 
impact on mortality.
Data Source and Populations
The FFS Medicare data comprised 5% Limited Data Set 
samples from the Centers for Medicare & Medicaid (CMS), 
which are randomly selected, for the years 2010-2012. These 
samples represented 4 313 885 person-years. The MA data 
came from the insurer for the years 2011-2013. The variables 
used from the MA data set were equivalent to those available 
in the FFS Medicare data set. The MA sample represented 
5 477 976 person-years. Both data sets represented the most 
recent data available at the time the study was initiated. 
Mortality data were derived from CMS denominator files for 
the FFS Medicare data set and from CMS Monthly 
Membership Reports for the MA data set. Individuals with 
end-stage renal disease (ESRD), non-US residence, Medicare 
secondary coverage, a group Medicare plan, or recognizably 
missing data were excluded.
As this study was conducted as part of the insurer’s nor-
mal business operations, it did not meet the Department of 
Health and Human Service’s regulatory definition of research 
under 45 Code of Federal Regulations 46.102(d), and thus 
did not require institutional review board approval or a 
Health Insurance Portability and Accountability Act (HIPAA) 
exemption—either for analysis of the insurer’s MA data or 
for analysis of the CMS 5% Limited Dataset. The authors 
have access to patient identifying information in the insurer’s 
MA claims and enrollment databases through the course of 
their daily job responsibilities and have accessed such data to 
complete this work. Corporate policy forbids analysts from 
accessing more than the minimum protected health informa-
tion (PHI) data necessary to fulfill specific business needs. 
Patient confidentiality is further protected by avoiding the 
reporting of data for subgroups with 10 or fewer individuals. 
The FFS data, provided in a CMS 5% Limited Dataset, were 
de-identified. In addition, the data use agreement with CMS 
additionally required that aggregate data be reported for no 
fewer than 11 individuals.
Model Development and Analysis
In the first step, the FFS Medicare data set was partitioned 
into 3 independent groups: a calibration (derivation) set 
and 2 testing sets, designed to all be comparable with 
respect to average calculated CMS risk score. The predic-
tor variables in CMS risk score models are Hierarchical 
Condition Categories (HCCs), which are based on prior-
year claims and reflect diagnosis as well as severity, and 
several demographic factors. The CMS model for the risk 
score considered in this study was based on a set of 70 
HCCs (see Table 1).
Next, a logistic regression model was designed, using 
SAS Enterprise Guide 5.1, to define the probability of death 
in a given year for the calibration group in the FFS Medicare 
data set. Demographics, Medicare eligibility characteristics, 
morbidity data (chronic conditions, CMS risk score, HCC 
count), and prior-year claims dollars (as a proxy for health 
risk) were considered for inclusion in the model as covariates 
(predictor variables).
Each possible predictor variable was considered for its 
potential to create bias in the model. As risk-adjusted pay-
ments create an incentive for MA plans to more completely 
document beneficiary diagnoses than is typical in FFS 
Medicare, inclusion of diagnosis-based variables as model 
predictors might elevate predicted mortality in the MA data 
set and thus artificially reduce the actual-to-predicted mor-
tality ratio, creating a bias in favor of MA. To reduce this 
potential bias, CMS risk score was omitted from the list of 
variables eligible for the model. However, a variable for an 
individual’s total number of HCCs (HCC count) remained 
eligible for the model, as did several variables reflecting the 
presence of chronic or acute conditions (see Table 1). 
Variables for diabetes and renal disease were omitted because 
of pending changes with respect to these disease areas in the 
CMS HCC model.9 Next, a forward stepwise selection pro-
cess was used to determine which of the eligible variables 
would be included in the final model. Each variable was 
assessed for contribution to the overall model fit using the 
residual chi-square test with a significance requirement of 
P = .05. Of the variables considered, only heart arrhythmia 
and panel year were omitted from the final model. In the 
final model, each variable had a P value <.01 according to 
the chi-square test.
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A final sensitivity analysis was then conducted by assess-
ing the accuracy of models with different combinations of 
variables. The final model with the retained condition vari-
ables plus HCC count had greater accuracy at the individual 
level (80.2% concordance) than that of a model with the 
chronic conditions only (78.7% concordance) and that of a 
model with demographic variables only (71.2% concor-
dance). Furthermore, the actual-to-predicted ratio in the 
model with condition variable plus HCC count was less 
favorable to MA (ratio, 0.8042) than the model with demo-
graphics only (ratio, 0.7875). Thus, inclusion of the selected 
morbidity measures actually yielded a more conservative 
estimate of MA-FFS differences, despite potential coding 
bias. The tau-c statistic for the final model was 0.809, which 
signified a relatively strong association between predicted 
and actual mortality rates.
Although prior-year claims dollars was considered as a 
predictive variable, it was ruled out due to its potential as a 
source of bias. While prior-year spending has been shown to 
be a good predictor of morbidity, differences in spending 
between MA and FFS Medicare would be confounded by 
differences in reimbursement models, types of benefits, and 
out-of-pocket spending caps.
After selection of the predictor variables, the model was fit 
to the calibration group, which represented 1 437 937 person-
years for 2010-2012. The final set of predictor variables is pre-
sented in Table 1. The resulting odds ratios for the calibration 
group are presented in Table S1 in the Supplementary Material.
When applied to the first FFS Medicare testing group, 
the model produced an actual-to-predicted mortality ratio 
of 1.0008. Out of the 1 437 880 individuals in the group, 
predictions were off only by 49 deaths, producing a Z score 
of 0.21. The actual-to-predicted ratios by subgroup (eg, 
subgroups defined by HCC count or gender) were checked 
to assure that the model maintained group-level accuracy 
across the subgroups as well as for the overall testing group. 
Ratios remained close to 1.00 (range, 0.9368-1.2017, with 
the extremes being tied to relatively small subgroups), and 
37 of 40 Z scores were within 2 standard deviations. Given 
these indications of group-level accuracy in the first testing 
group, the model was not tested in the second testing group. 
A plot showing model accuracy at various levels of pre-
dicted mortality is included in Figure S1 in the 
Supplementary Material. This revealed some bias for indi-
viduals at the highest level of predicted mortality, but with 
a good model fit overall.
Finally, the resulting model was applied to the MA data 
set to yield the expected mortality rate had the MA enroll-
ees been in FFS Medicare. Additional analysis was con-
ducted according to subgroups defined by gender, age, 
race, dual eligibility in the prior year, HCC count, plan 
type, duration of Medicare eligibility, and the basis of eli-
gibility for Medicare (age or disability). The statistical sig-
nificance of the difference between actual and predicted 
mortality overall and within each subgroup was assessed 
by Z scores.






Cancer 7, 8, 9, 10
Congestive heart failure 80
Rheumatoid arthritis, severe hematological 
disorder, or muscular dystrophy
38, 44, 70
Cardiovascular disease 92, 104, 105
Chronic condition 1, 5, 7, 8, 9, 10, 15, 16, 17, 18, 19, 21, 25, 26, 27, 32, 33, 37, 38, 44, 45, 52, 54, 55, 67, 
68, 69, 70, 71, 72, 73, 74, 80, 83, 92, 100, 101, 105, 107, 108, 119, 130, 131, 132, 
148, 149, 157, 174, 176, 177
Specific acute condition 2, 31, 51, 75, 77, 78, 79, 81, 82, 95, 96, 104, 111, 112, 150, 154, 155, 158, 161, 164
Chronic lung disease 108
Disability (vs aged-in) eligibility NA
Newly eligible for Medicare NA
Dual eligibilityb in prior year NA
Dual eligibility in current year NA
Note. HCCs = Hierarchical Condition Categories; SSA = Social Security Administration.
aRace designations were derived from the SSA. As the SSA only classified race/ethnicity as white, black, other, or unknown prior to 1980 and as most 
current Medicare members were born prior to 1980, this study conformed to those categories.
bEligibility for Medicaid in addition to Medicare.
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Table 2. Mortality by Demographic Subgroup.
n (person-years) Actual mortality rate, % Predicted mortality,a % Actual/predicted rate (95% CI)
Gender
 Female 3 020 115 2.6 3.4 0.765 (0.761-0.770)
 Male 2 457 861 3.4 4.0 0.844 (0.839-0.849)
Age band
 <25 3282 0.5 0.4 1.373 (0.892-2.982)
 25-34 26 257 0.6 0.6 1.138 (0.980-1.354)
 35-44 87 785 1.0 0.9 1.031 (0.966-1.105)
 45-54 278 397 1.4 1.6 0.877 (0.852-0.902)
 55-64 781 103 1.7 2.2 0.762 (0.751-0.773)
 65-74 2 582 015 1.7 2.1 0.846 (0.839-0.853)
 75-84 1 308 047 4.1 5.2 0.785 (0.780-0.791)
 85-94 387 402 10.2 13.0 0.783 (0.777-0.789)
 ≥95 23 570 22.9 27.0 0.845 (0.829-0.862)
Raceb
 Black 666 270 2.6 3.6 0.728 (0.720-0.737)
 White 4 547 516 3.0 3.7 0.819 (0.815-0.822)
 Unknown 23 592 1.3 1.2 1.116 (1.001-1.261)
 Other 240 598 2.1 2.9 0.703 (0.689-0.720)
Prior-year dual eligibilityc
 Yes 804 411 3.8 4.6 0.679 (0.674-0.685)
 No 4 673 565 2.8 3.3 0.841 (0.837-0.845)
Note. CI = confidence interval; SSA = Social Security Administration.
aP < .001 for all absolute differences between actual and predicted mortality, except in the subgroup of unknown race (P < .9765) and in the age bands of 
20 (P < .9120), 30 (P < .9526), and 40 (P < .8155).
bRace designations were derived from the SSA. As the SSA only classified race/ethnicity as white, black, other, or unknown prior to 1980 and as most 
current Medicare members were born prior to 1980, this study conformed to those categories.
cEligibility for Medicaid in addition to Medicare.
Results
Study Population
The FFS Medicare calibration group and MA data set were 
similar in mean age (71.5 and 71.1 years, respectively), gender 
distribution (56% and 55% female), and clinical risk according 
to mean HCC count (1.55 and 1.58). Both groups were pre-
dominately white (84.8% and 83.0%), but the FFS Medicare 
group included fewer black participants (9.3% vs 12.2%) and 
slightly more other nonwhite participants (5.5% vs 4.4%). FFS 
Medicare participants were more likely to have dual eligibility 
in the prior year (20.2% vs 14.7%). The MA population was 
more heavily concentrated in the South (64% vs 40% of FFS 
Medicare participants). More than 66% of MA participants 
were in newer, non-HMO plan types. Population characteris-
tics are presented in Table S2 of the Supplementary Material.
Predicted Versus Actual Mortality in MA
When the mortality regression model was applied to the MA 
data set, predicted mortality was 3.7%, whereas actual mortal-
ity was 2.9% (P < .001 for the difference). These results com-
pare with both a predicted and an actual rate of 4.3% 
(2010-2012) in the FFS Medicare calibration group. The differ-
ence in predicted mortality between MA and FFS Medicare 
(3.7% vs 4.3%) suggests that the MA members were healthier, 
which could explain the lower actual mortality in the MA pop-
ulation versus FFS Medicare (2.9% vs 4.3%). Nevertheless, the 
actual-to-predicted ratio for the MA data set was <1.00 (0.804; 
95% confidence interval [CI], 0.801-0.808). In other words, 
MA participants were less likely to die in a 1-year time frame 
than would have been expected for individuals with a similar 
risk profile enrolled in FFS Medicare. These results suggest 
that factors other than demographics and morbidity are respon-
sible for mortality differences.
Demographic Subgroups
Actual-to-predicted mortality ratios were lower (more favor-
able to MA) in individuals above the age of 50 compared 
with younger members and lower in women compared with 
men, but ratios favored MA in both women and men. All 
subgroups with known race had actual mortality rates that 
were lower than predicted. Compared with the white sub-
group, nonwhite subgroups (black, other) exhibited consid-
erably lower actual-to-predicted ratios even though predicted 
mortality was comparable between the black and white sub-
groups. The actual-to-predicted ratio was also lower in the 
subgroup with dual eligibility in the prior year, compared 
with other participants (see Table 2).
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Morbidity Subgroups
The difference between actual and expected mortality was 
more pronounced among those individuals with the highest 
morbidity, as represented by number of HCCs. Members 
without any HCCs had low and similar predicted and actual 
mortality rates. As the number of HCCs increased, both 
actual and predicted mortality increased, but actual mortality 
increased more gradually so that the absolute difference 
between them grew. Relative differences, expressed as 
actual-to-predicted ratios, consistently favored MA in indi-
viduals with an HCC count ≥1 (see Figure 1).
Subgroups Defined by Plan Type and Eligibility 
Characteristics
Individuals with Local Preferred Provider Organization (LPPO) 
and Regional Preferred Provider Organization (RPPO) plan 
types had the lowest actual and predicted mortality rates. Those 
with an HMO plan had the highest predicted mortality but the 
lowest actual-to-predicted ratio, suggesting that the greatest 
effect relative to FFS Medicare occurred in HMO plans. The 
Private Fee-For-Service (PFFS) subgroup showed the least dif-
ference between actual and predicted mortality. Actual-to-
predicted mortality ratios were lower in members who had been 
eligible for Medicare for more than 1 year compared with mem-
bers who had become eligible in the current year. No difference 
in actual-to-predicted mortality was shown between individuals 
who qualified for Medicare because of disability and those who 
qualified on the basis of age (see Table 3).
Post Hoc Analysis
As the analysis consistently showed lower than expected 
mortality rates in the MA population, a post hoc analysis 
was conducted to investigate participation in a relatively 
new care management service as one possible driver of this 
improvement. This holistic service is designed for individu-
als who not only have serious medical needs but who also 
are expected to benefit from assistance with a range of other 
needs. For the year 2013, the first year of the program with 
substantial participation, members who were eligible and 
participating in the program experienced a mortality rate 
that was 3.1 percentage points lower than that for those who 
were eligible but not participating (6.4% vs 9.5%), while 
both groups had a similar predicted mortality rate (partici-
pating, 7.3%; not participating, 7.2%). The actual-to-pre-
dicted ratio for participants favored MA, but the ratio for 
eligible nonparticipants did not, suggesting that the benefit 
of MA for this subgroup was mediated through the care ser-
vice. However, these findings may reflect selection bias as 
participation is voluntary, and these early findings may not 
be replicated as the program matures. Furthermore, the 
accuracy of the model in this subgroup with high morbidity 
could not be tested during model development because there 
was no way to identify a comparable subgroup in the FFS 
Medicare data set.
Discussion
Actual mortality in the MA data set was less than risk-
adjusted, expected mortality, both overall and in most sub-
groups. Some of the largest differences between actual and 
predicted mortality were observed in certain vulnerable sub-
groups defined by race or income, and in HMO plans as 
opposed to PFFS or PPO plans. Although subject to the pos-
sibility of unmeasured confounders, these findings provide 
an important contribution to the sparse body of literature 
evaluating the relationship between MA participation and 
mortality.
Figure 1. Mortality by Hierarchical Condition Category count.
Note. P < .001 for all absolute differences between actual and predicted mortality, except in the subgroup of HCC count 0 (P < 1.000).
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Findings in the Context of Other Research
Only 1 other study published since 2000 has compared gen-
eral mortality as an outcome measure between FFS Medicare 
and MA.8 Dowd and colleagues found no difference in 2-year 
mortality between FFS Medicare and MA HMOs when con-
sidering observed confounders. In contrast, the present study 
suggested that MA is associated with lower adjusted mortal-
ity. Several aspects of the Dowd study and the present study 
may explain the discordant findings (Dowd vs present study): 
largely self-reported versus objective observed confounders, 
1996-2000 versus 2010-2012 and 2011-2013 time frames, 
sample size 15 164 survey respondents versus 6 913 915 per-
son-years, all MA providers versus a single provider, and 
exclusion versus inclusion of individuals in Medicare 
because of disability and individuals eligible for Medicaid.
Some comparative studies have evaluated mortality pri-
marily as a baseline indicator of health status rather than as 
an outcome. Krumholz et al found that the difference in mor-
tality rates between the fee-for service and MA populations 
remained stable from 2003 through 2013, with a difference 
(0.72-0.89 percentage point) favoring MA.5 This difference 
compares with an unadjusted difference of 1.4%, also favor-
ing MA, in the present study. Song has shown that as MA 
attracts a greater share of the market, the health status of MA 
populations improves relative to FFS Medicare populations.7 
The studies by Krumholz et al and Song suggest the possibil-
ity of a selection bias favoring MA, but in contrast to the 
present study, neither adjusted for morbidity. The authors of 
both studies noted that their analysis could not assess the 
extent to which MA plans contribute to the health of their 
members as opposed to attracting healthier members.
Unobserved Confounding and Other Factors 
Affecting Mortality Differences
Between 2004 and 2007, CMS policy efforts sought to mini-
mize favorable selection in MA. To the extent that favorable 
selection persists, it may have created bias in the present study 
in favor of MA and thus reduced the actual-to-predicted mor-
tality ratio. One group investigating the impact of these policy 
changes has concluded that although some selection bias favor-
ing MA plans remains, it has been substantially reduced.10-13 In 
the present study, predicted mortality was indeed lower in the 
MA population than in the FFS Medicare population, which 
suggests that healthier individuals do tend to choose or remain 
in MA. However, the actual-to-predicted mortality ratios sug-
gested that differences in baseline morbidity do not fully 
explain mortality differences; that is, either program factors or 
patient factors other than baseline chronic disease are likely 
responsible for the observed findings favorable to MA.
Various aspects of MA plans may explain lower mortality 
rates, such as the use of alternative payment models or empha-
sis on preventive care and disease management. In this study, 
the greatest reduction from predicted mortality was in HMO 
plans, which account for the majority of MA participants 
across all contractors, suggesting that HMO plans are particu-
larly effective relative to the other plan types assessed. 
However, as the HMO subgroup also had the highest pre-
dicted mortality, further study is needed to assess whether a 
benefit was observed in this subgroup simply because MA is 
particularly effective in less healthy individuals.
Alternatively, it is possible that the observation of lower 
mortality rate in MA, even after correction for differences in 
morbidity, reflects unmeasured patient factors that favor 
MA. For example, individuals who choose or stay in MA 
may have better lifestyle habits or health-seeking behaviors 
that help them achieve better outcomes even when demo-
graphic and clinical factors put them at risk. Interestingly, an 
additional analysis in the aforementioned study by Dowd 
et al8 used novel statistical techniques to adjust for potential 
unobserved as well as observed confounders and showed 
2-year mortality to be lower in MA, whereas analysis based 
only on observable confounders had shown no difference 
between MA and FFS Medicare. Statistical significance 
in the analysis that included unobservable confounders 









 Local PPO 1 378 606 2.7 3.1 0.891 (0.884-0.900)
 Regional PPO 937 839 2.8 3.1 0.902 (0.892-0.912)
 Private Fee-for-Service 766 136 3.4 3.5 0.980 (0.969-0.991)
 HMO 2 395 395 3.0 4.3 0.695 (0.691-0.699)
Duration of Medicare eligibility
 Newly eligible for Medicare 613 926 0.8 1.0 0.855 (0.834-0.877)
 Eligible for Medicare in previous year 4 864 050 3.2 4.0 0.803 (0.799-0.806)
Reason for Medicare eligibility
 Aged-in 3 961 609 3.1 3.8 0.806 (0.803-0.810)
 Previously disabled 1 516 367 2.6 3.2 0.798 (0.791-0.805)
Note. CI = confidence interval; PPO = Preferred Provider Organization; HMO = Health Maintenance Organization.
aP < .001 for all absolute differences between actual and predicted mortality.
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depended on how the variable representing geographic fixed 
effects was defined. Dowd and colleagues described these 
findings as evidence of a selection bias against MA.8 Other 
examples of assessing the effect of unmeasured confounders 
in comparisons of MA and FFS Medicare were not identified 
in the literature.
Some research has suggested that mortality differences 
between FFS Medicare and MA reflect the fact that switch-
ing from MA to FFS Medicare is more common than switch-
ing in the reverse direction among individuals in nursing 
homes or inpatient facilities, that is, among individuals most 
likely to die in the near term.4 The present study’s findings 
neither contradicted nor supported those findings but rather 
showed that for a given MA panel, mortality was lower than 
morbidity and demographic risk would predict.
Subgroups
Important findings from this study included evidence that MA 
may be especially effective in addressing health care dispari-
ties in vulnerable subgroups: nonwhite groups and individu-
als with low income as reflected by dual eligibility. Previous 
research has also suggested relatively greater MA benefits for 
minorities.14,15 These findings are relevant in light of national 
policy. The Healthy People Initiative of the Centers for 
Disease Control and Prevention (CDC) has set a goal of elim-
inating health disparities by 2020 in groups that are disadvan-
taged due to factors such as race/ethnicity, socioeconomic 
status, and disability.16 In keeping with these concerns, the 
CMS Office of Minority Health recently released for the first 
time MA quality data stratified by race/ethnicity.17
Limitations
Certain factors may detract from the comparability of the 
MA and FFS Medicare data sets. The Northeast and the West 
geographic regions were underrepresented in the MA study 
population due to low membership in those areas, and the 
FFS Medicare data set was not selected to match the geo-
graphic distribution of the MA population. However, a visual 
inspection of state-specific actual mortality rates showed that 
in both the FFS Medicare and MA data sets, states in the 
Northeast and West regions were more likely to have rela-
tively lower mortality rates. Thus, any bias that might have 
resulted from these geographic differences would likely have 
increased the observed MA actual-to-predicted mortality 
ratio, making results less favorable to MA. In addition, pre-
vious research has shown that when patients in FFS Medicare 
moved to another hospital referral region, the increase in the 
average number of diagnoses was considerably greater if 
they moved to a region characterized by high-intensity prac-
tice patterns (reflected in utilization as well as coding).18 If 
the 2 populations differed with respect to the mix of regions 
with low-intensity and high-intensity practice patterns, irre-
spective of whether patients were in FFS Medicare or MA, 
results could be biased in one direction or the other. The 
3-year time frame differed by 1 year between the 2 data sets, 
but the authors do not know of a reason this would have sub-
stantially altered results, given the stability of mortality rates 
in both FFS Medicare and MA in recent years.5 Finally, dual 
eligibility status represents a limited means of adjusting for 
socioeconomic differences between the 2 populations.
Several limitations inherent to study design apply to this 
work. First, as noted previously, unmeasured confounding 
may have biased results. Second, some individuals in the MA 
data set may not have been enrolled long enough for their 
survival to be attributable to participation in the plan. 
However, as the average tenure within any 1-year panel of 
individuals in the insurer’s MA plans is approximately 4 
years, findings can reasonably be assumed to reflect an effect 
of participation in MA. The analysis may in fact underesti-
mate the eventual benefit as the total cumulative enrollment, 
over time, is substantially greater than 4 years for the MA 
population evaluated by this study.
Claims data (whether from FFS Medicare or an MA plan) 
are subject to missing values and incorrect coding, and the 
FFS Medicare sample may have been more likely than the MA 
data set to have missing morbidity data. The extent of this dis-
crepancy is unknown, but selection of predictor variables was 
designed to minimize the difference and sensitivity testing, 
using models with and without morbidity variables, suggested 
that study results could not be fully attributed to coding bias.
The authors acknowledge that the results may not be gener-
alizable to MA populations served by other insurers. However, 
one advantage of the model derived from the CMS sample is 
that it can be applied to other MA populations to generate 
actual-to-predicted ratios specific to those populations.
Conclusion
Overall, this study showed an association between enrollment 
in the insurer’s MA plan and reduced mortality after adjust-
ment for demographics and morbidity. The differences 
between actual and predicted mortality were particularly pro-
nounced in low income, nonwhite race, and HMO plan type 
subgroups. These findings suggest that differences in morbid-
ity do not fully explain differences in mortality between the 2 
programs. Findings should be interpreted with some caution 
because of the previously acknowledged study limitations.
Additional research is needed to more directly assess the 
effect of MA on mortality. Longitudinal cohort studies track-
ing concurrent MA and FFS Medicare groups for several 
years are needed. The apparent greater effect of MA in sub-
populations with more chronic disease merits further explo-
ration to identify the operant factors. The impact of duration 
of enrollment on mortality differences might also be explored 
to better assess the plausibility of a causal relationship 
between MA participation and reduced mortality. Methods 
for assessing the effect of selection bias are needed. As the 
present study applied to a single MA provider’s population, 
similar analyses in other MA populations are needed to help 
establish the effect of MA enrollment.
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